Crispr Therapeutics Ag (NQ: CRSP )

48.85 +2.44 (+5.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,383,033
Open 47.77
Bid (Size) 48.54 (2)
Ask (Size) 48.97 (1)
Prev. Close 46.41
Today's Range 47.23 - 48.94
52wk Range 37.55 - 91.10
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Got the Market Sell-Off Blues? Do These 3 Things Right Now
You aren't powerless in the face of what the market throws at you. 
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is." 
Via Benzinga

Performance

YTD
-26.05%
-26.05%
1 Month
-14.98%
-14.98%
3 Month
-14.24%
-14.24%
6 Month
-38.20%
-38.20%
1 Year
+0.35%
+0.35%

More News

Read More
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Via The Motley Fool
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
Via InvestorPlace
3 Small-Cap Stocks to Buy at a 52-Week Low
Via InvestorPlace
3 Gene Editing Stocks Shaping the Future of Medicine
Via InvestorPlace
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Blue Chips, Small Caps Extending Their Breakout
Via Talk Markets
Topics Stocks
Exposures US Equities
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
Via The Motley Fool
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
Via Benzinga
Topics ETFs
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Via MarketBeat
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Via InvestorPlace
7 Growth Stocks to Invest $500 In and Cash Out $100K by 2030
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.